The adenosine pathway in immuno-oncology

Area of Science:

• Immuno-oncology
• Cancer Therapeutics
• Adenosine Signaling

Background:

• Cancer immunotherapy has revolutionized treatment but many patients lack benefit.
• Extracellular adenosine (eADO) signaling is a key immunosuppressive pathway in the tumor microenvironment.
• Next-generation immuno-oncology agents targeting eADO are emerging.

Purpose of the Study:

• To review the pathophysiological role of eADO in regulating anti-tumor immunity.
• To discuss the therapeutic potential and limitations of targeting the eADO pathway in cancer.
• To explore biomarker strategies for adenosine-targeted cancer therapy.

Main Methods:

• Review of current literature on eADO signaling in cancer.
• Analysis of the mechanisms by which eADO affects innate and adaptive immune responses.
• Discussion of clinical trial data and future directions for eADO inhibitors.

Main Results:

• The adenosinergic axis, induced by hypoxia and inflammation, broadly suppresses immune responses.
• Inhibition of eADO-generating enzymes or receptors can enhance T cell and NK cell function.
• Targeting eADO can suppress pro-tumorigenic myeloid cells and improve antigen presentation.

Conclusions:

• Inhibiting eADO signaling represents a promising strategy to enhance anti-tumor immunity and improve patient outcomes.
• Further research and clinical trials are needed to optimize adenosine-targeted therapies.
• Biomarker development is crucial for patient selection and treatment stratification.